Latest argenx News & Updates

See the latest news and media coverage for argenx. We track all announcements, press releases, and industry mentions in real time, all in one place.

argenx

Immunology-focused biopharmaceutical company

argenx.com

Headquarters: Boston, United States
Founded year: 2008
Company type: Public company
Number of employees: 2,300–5,000
Industry: Pharmaceuticals

Last updated October 22

Latest news about argenx

In short: argenx posted strong sales growth, acquired Forte Biosciences, reported positive myositis data, and discontinued a Sjögren's study.

Company announcements

October 22 argenx

argenx reports Q3 2026 results with $1.7bn sales growth

Revenue rose 54% year-over-year to $1.7 billion. The company advances FB102 into Phase 3 for celiac disease and continues pipeline developments across immunology indications.

October 19 argenx

argenx presents ALKIVIA Phase 3 results in autoimmune myositis at ACR

Results show efgartigimod provides clinically meaningful improvements in muscle strength for immune-mediated necrotizing myopathy and dermatomyositis patients compared to placebo.

October 8 argenx

argenx reports positive Phase 2 results for FB102 in celiac disease

The drug met its primary endpoint preventing intestinal damage. argenx plans to advance the first-in-class CD122 inhibitor into Phase 3 trials.

October 8 argenx

argenx discontinues Phase 3 Sjögren's study

The UNITY trial stopped for futility. The IDMC concluded the study could not meet its primary endpoint.

Media coverage

October 22 PharmaShots

The US FDA Accepts argenx’s sBLA for Vyvgart and Vyvgart Hytrulo with Priority Review for Pediatric Generalized Myasthenia Gravis (gMG) - PharmaShots

Shots:The US FDA has accepted argenx’s sBLA for Vyvgart (efgartigimod alfa-fcab, IV) & Vyvgart Hytrulo (efgartigimod alfa & hyaluronidase-qvfc, SC) to treat pediatric generalized myasthenia...

October 22 Reuters

Argenx says Vyvgart sales rose 54% in third quarter

Belgian-Dutch pharmaceutical firm argenx said on Thursday that global sales of its leading autoimmune drug ‌Vyvgart rose 54% in the third quarter, as it...

October 19 The Manila Times

argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026

Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements...

October 14 FiercePharma

Argenx confirmatory trial update for Vyvgart puts small dent in strong Q3

Yesterday, argenx's stock slipped by more than 2%—with its shares still down slightly as of Friday morning—after the Dutch pharma...

Never miss news about argenx

Track argenx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

argenx competitors & trending companies

Browse news for competitors to argenx and other trending companies.